Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

“The Idea is to Help People Achieve Greater Success and Liberty”: A Qualitative Study of Expanded Methadone Take-Home access in Opioid use Disorder Treatment
Leslie W. Suen, Stacy Castellanos, Neena Joshi, et al.
Substance Abuse (2022) Vol. 43, Iss. 1, pp. 1147-1154
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy
Noa Krawczyk, Bianca Rivera, Emily Levin, et al.
The Lancet Public Health (2023) Vol. 8, Iss. 3, pp. e238-e246
Open Access | Times Cited: 57
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
Alison E. Adams, Sarin Blawatt, Tianna Magel, et al.
Substance Abuse Treatment Prevention and Policy (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 19
Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
Eugenia Oviedo‐Joekes, Sophia Dobischok, José Carvajal, et al.
BMC Health Services Research (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder
Ashish P. Thakrar, Jarratt D. Pytell, Kenneth B. Stoller, et al.
Journal of Substance Use and Addiction Treatment (2023) Vol. 150, pp. 209055-209055
Open Access | Times Cited: 14
Methadone’s Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction)
Leslie W. Suen, Michael Incze, Caty Simon, et al.
Substance Use & Addiction Journal (2024) Vol. 45, Iss. 3, pp. 337-345
Closed Access | Times Cited: 6
Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID
Beth E. Meyerson, Keith Gunnar Bentele, Danielle M. Russell, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0274094-e0274094
Open Access | Times Cited: 22
Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
Alison E. Adams, Sarin Blawatt, Scott Macdonald, et al.
International Journal of Drug Policy (2023) Vol. 117, pp. 104058-104058
Open Access | Times Cited: 11
Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review
Victoria Panwala, Paul J. Joudrey, Melanie Kowalski, et al.
Journal of Substance Use and Addiction Treatment (2023) Vol. 152, pp. 209086-209086
Open Access | Times Cited: 10
State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID‐19 onset
Ignacio Bórquez, Arthur Robin Williams, Mei‐Chen Hu, et al.
Addiction (2025)
Closed Access
Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland
Eshan U. Patel, Suzanne M. Grieb, Abigail K. Winiker, et al.
Harm Reduction Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Exploring the impact of the COVID-19 pandemic on healthcare and substance use service access among women who inject drugs: a qualitative study
Lyra Cooper, Joseph G. Rosen, Leanne Zhang, et al.
Harm Reduction Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 8
Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey
Sarah Brothers, Adam Palayew, Caty Simon, et al.
Harm Reduction Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 7
“Get in and get out, get on with life”: Patient and provider perspectives on methadone van implementation for opioid use disorder treatment
Leslie W. Suen, Scott Steiger, Brad Shapiro, et al.
International Journal of Drug Policy (2023) Vol. 121, pp. 104214-104214
Open Access | Times Cited: 7
Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review
Cayley Russell, Jenna Ashley, Farihah Ali, et al.
International Journal of Drug Policy (2024) Vol. 127, pp. 104343-104343
Open Access | Times Cited: 2
“It didn’t hurt me”: patients’ and providers’ perspectives on unsupervised take-home doses, drug diversion, and overdose risks in the provision of medication for opioid use disorder during COVID-19 in San Juan, Puerto Rico
Roberto Abadie, Celia B. Fisher
Harm Reduction Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 2
Overdose deaths before and during the COVID-19 pandemic in a US county
C. Hendricks Brown, Kimberly Johnson, Holly A. Hills, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 2
Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore
Tolulope M. Abidogun, Thomas O. Cole, Ebonie Massey, et al.
Journal of Substance Use and Addiction Treatment (2023) Vol. 145, pp. 208946-208946
Open Access | Times Cited: 6
Methadone’s Moment
Michael Incze, Caty Simon, Leslie W. Suen
JAMA (2024)
Closed Access | Times Cited: 2
“That Line Just Kept Moving”: Motivations and Experiences of People Who Use Methamphetamine
Callan Fockele, Sophie C. Morse, Jenna van Draanen, et al.
Western Journal of Emergency Medicine (2023) Vol. 24, Iss. 2, pp. 218-227
Open Access | Times Cited: 4
Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis
Gary Qian, Keith Humphreys, Jeremy D. Goldhaber‐Fiebert, et al.
Drug and Alcohol Dependence (2024) Vol. 256, pp. 111112-111112
Closed Access | Times Cited: 1
Effectiveness of take-home methadone treatment among patients with opioid use disorders during COVID-19: A systematic review
Shabnam Naher, Sabbir Pervez, Feroz Ahmed, et al.
Health Sciences Review (2024) Vol. 12, pp. 100195-100195
Open Access | Times Cited: 1
“I still can feel the sickness”: Withdrawal experiences of people on methadone maintenance treatment
David Frank, Alex S. Bennett, Charles M. Cleland, et al.
Journal of Substance Use and Addiction Treatment (2024) Vol. 170, pp. 209616-209616
Closed Access | Times Cited: 1
“I can’t see anything but upside”: A qualitative study of clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program
Eugenia Oviedo‐Joekes, Sophia Dobischok, José Carvajal, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 3
Individualizing methadone treatment with split dosing: An underutilized tool
Hannan M. Braun, Ruth A. Potee
Journal of Substance Use and Addiction Treatment (2023) Vol. 152, pp. 209096-209096
Closed Access | Times Cited: 3
What can we learn from COVID-19 to improve opioid treatment? Expert providers respond
Lesley M. Harris, Jeanne C. Marsh, Tenie Khachikian, et al.
Journal of Substance Use and Addiction Treatment (2023) Vol. 154, pp. 209157-209157
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top